nach oben

Erschienen in:

15.11.2023 | Original Article

Proton Pump Inhibitors Increases Longitudinal Risk of Mortality, Decompensation, and Infection in Cirrhosis: A Meta-Analysis

verfasst von: Zhen Yu Wong, Jia Hong Koh, Mark Muthiah, Benjamin Koh, Elden Yen Hng Ong, Christen En Ya Ong, Kai Qi Ou, Wen Hui Lim, Darren Jun Hao Tan, Douglas Chee, Kewin Tien Ho Siah, Yujun Wong, Apichat Kaewdech, Karn Wijarnpreecha, Anand V. Kulkarni, Benjamin Nah, Daniel Q. Huang, Mazen Noureddin, Cheng Han Ng, Margaret Teng

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Background/Aims

Proton pump inhibitors (PPIs) are frequently prescribed to cirrhotic patients, but there is limited longitudinal evidence regarding their effects. This study aimed to assess the impact of PPIs on adverse events in cirrhotic patients.

Methods

A comprehensive search was conducted using the Medline and Embase databases to identify relevant articles. Pooled hazard ratios (HRs) using DerSimonian and Laird random-effects model were calculated to evaluate the risk of adverse events such as long-term mortality, hepatic decompensation, hepatic encephalopathy (HE), spontaneous bacterial peritonitis (SBP), and overall infection in cirrhotic patients with PPI use.

Results

The analysis included 28 studies with 260,854 cirrhotic patients. The prevalence of PPI use among cirrhotic patients was 55.93%. The use of PPIs was not significantly associated with short-term mortality in cirrhotic patients. However, long-term mortality (HR 1.321, 95% CI 1.103–1.581, P = 0.002), decompensation (HR 1.646, 95% CI 1.477–1.835, P < 0.001), HE (HR 1.968, 95% CI 1.372–2.822, P < 0.001), SBP (HR 1.751, 95% CI 1.649–1.859, P < 0.001), and infection (HR 1.370, 95% CI 1.148–1.634, P < 0.001) were significantly associated with PPI use. Sensitivity analysis with prospective studies yielded similar results.

Conclusion

PPIs should be reserved for appropriate indications at lowest effective dose for cirrhotic patients due to the potential harm.

Nur mit Berechtigung zugänglich

Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650–2666.PubMedCrossRef

The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245–266.

Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. The Lancet. 2014;383:1749–1761.CrossRef

Li DK, Chung RT. Use of proton pump inhibitors in chronic liver diseases. Clinical Liver Disease. 2017;10:148.PubMedCrossRef

Chavez-Tapia NC, Tellez-Avila FI, Garcia-Leiva J, Valdovinos MA. Use and overuse of proton pump inhibitors in cirrhotic patients. Medical science monitor. 2008;14:CR468-CR472.

Shaheen NJ, Stuart E, Schmitz SM et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology. 2005;41:588–594.PubMedCrossRef

Huang K-W, Kuan Y-C, Luo J-C, Lin C-L, Liang J-A, Kao C-H. Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis. European Journal of Internal Medicine. 2016;32:91–95.PubMedCrossRef

Min Y, Lim K, Min BH et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Alimentary pharmacology & therapeutics. 2014;40:695–704.CrossRef

de Vos M, De Vroey B, Garcia BG et al. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Liver International. 2013;33:1316–1323.PubMedCrossRef

10.

Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Official journal of the American College of Gastroenterology| ACG. 2009;104:1130–1134.

11.

Terg R, Casciato P, Garbe C, et al. Study Group of Cirrhosis Complications of the Argentine Association for the Study of Liver Disease. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. J Hepatol. 2015;62:1056–1060.

12.

Mandorfer M, Bota S, Schwabl P et al. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. PloS one. 2014;9:e110503.PubMedPubMedCentralCrossRef

13.

van Vlerken LG, Huisman EJ, van Hoek B et al. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. European Journal of Clinical Investigation. 2012;42:760–767.PubMedCrossRef

14.

De Roza MA, Kai L, Kam JW et al. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World journal of gastroenterology. 2019;25:4933.PubMedPubMedCentralCrossRef

15.

Nardelli S, Gioia S, Ridola L, Farcomeni A, Merli M, Riggio O. Proton pump inhibitors are associated with minimal and overt hepatic encephalopathy and increased mortality in patients with cirrhosis. Hepatology. 2019;70:640–649.PubMedCrossRef

16.

Dultz G, Piiper A, Zeuzem S, Kronenberger B, Waidmann O. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Alimentary pharmacology & therapeutics. 2015;41:459–466.CrossRef

17.

Cole H, Pennycook S, Hayes P. The impact of proton pump inhibitor therapy on patients with liver disease. Alimentary pharmacology & therapeutics. 2016;44:1213–1223.CrossRef

18.

Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.PubMedPubMedCentralCrossRef

19.

Hutton B, Salanti G, Caldwell DM et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Annals of Internal Medicine. 2015;162:777–784.PubMedCrossRef

20.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986;7:177–188.PubMedCrossRef

21.

Fletcher J. What is heterogeneity and is it important? Bmj. 2007;334:94–96.PubMedPubMedCentralCrossRef

22.

Bell A, Fairbrother M, Jones K. Fixed and random effects models: making an informed choice. Quality & Quantity. 2019;53:1051–1074.CrossRef

23.

Tufanaru C, Munn Z, Stephenson M, Aromataris E. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. International journal of evidence-based healthcare. 2015;13:196–207.PubMedCrossRef

24.

Lee KS, Zhang JJY, Nga VDW et al. Tenets for the Proper Conduct and Use of Meta-Analyses: A Practical Guide for Neurosurgeons. World Neurosurg. 2022;161:291-302.e291.PubMedCrossRef

25.

Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74:785–794.PubMedCrossRef

26.

Hill AB. THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION? Proc R Soc Med. 1965;58:295–300.PubMedPubMedCentral

27.

Fedak KM, Bernal A, Capshaw ZA, Gross S. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. Emerg Themes Epidemiol. 2015;12:14.PubMedPubMedCentralCrossRef

28.

Degelman ML, Herman KM. Smoking and multiple sclerosis: A systematic review and meta-analysis using the Bradford Hill criteria for causation. Mult Scler Relat Disord. 2017;17:207–216.PubMedCrossRef

29.

Jacques ROC, Massignan LDS, Winkler MS, Balbinot RS, Balbinot SS, Soldera J. Acute-on-chronic liver failure is independently associated with lower survival in patients with spontaneous bacterial peritonitis. Arq Gastroenterol. 2021;58:344–352.PubMedCrossRef

30.

Miozzo SAS, John JA, Appel-da-Silva MC, Dossin IA, Tovo CV, Mattos AA. Influence of proton pump inhibitors in the development of spontaneous bacterial peritonitis. World J Hepatol. 2017;9:1278–1285.PubMedPubMedCentralCrossRef

31.

Bishay K, Tandon P, Fisher S et al. Clinical Factors Associated with Mortality in Cirrhotic Patients Presenting with Upper Gastrointestinal Bleeding. J Can Assoc Gastroenterol. 2020;3:127–134.PubMedCrossRef

32.

Sun S, Ye W, Zhao R et al. Proton Pump Inhibitor Therapy Does Not Affect Prognosis of Cirrhosis Patients With Acute Decompensation and Acute-on-Chronic Liver Failure: A Single-Center Prospective Study. Front Med (Lausanne). 2021;8:763370.PubMedPubMedCentralCrossRef

33.

Abdel-Razik A, Abdelsalam M, Gad DF et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: novel predictors. Eur J Gastroenterol Hepatol. 2020;32:718–726.PubMedCrossRef

34.

Tergast TL, Wranke A, Laser H et al. Dose-dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. Liver Int. 2018;38:1602–1613.PubMedCrossRef

35.

Janka T, Tornai T, Borbély B et al. Deleterious effect of proton pump inhibitors on the disease course of cirrhosis. Eur J Gastroenterol Hepatol. 2020;32:257–264.PubMedCrossRef

36.

Sakamaki A, Kamimura K, Yokoo T et al. The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan. Medicine (Baltimore). 2021;100:e26902.PubMedPubMedCentralCrossRef

37.

Kwon JH, Koh SJ, Kim W et al. Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. J Gastroenterol Hepatol. 2014;29:775–781.PubMedCrossRef

38.

González-González JA, García-Compean D, Vázquez-Elizondo G, Garza-Galindo A, Jáquez-Quintana JO, Maldonado-Garza H. Nonvariceal upper gastrointestinal bleeding in patients with liver cirrhosis. Clinical features, outcomes and predictors of in-hospital mortality. A prospective study. Ann Hepatol. 2011;10:287–295.

39.

Hung TH, Lee HF, Tseng CW, Tsai CC. Effect of proton pump inhibitors in hospitalization on mortality of patients with hepatic encephalopathy and cirrhosis but no active gastrointestinal bleeding. Clin Res Hepatol Gastroenterol. 2018;42:353–359.PubMedCrossRef

40.

Teng W, Chen WT, Ho YP et al. Predictors of mortality within 6 weeks after treatment of gastric variceal bleeding in cirrhotic patients. Medicine (Baltimore). 2014;93:e321.PubMedPubMedCentralCrossRef

41.

Cole HL, Pennycook S, Hayes PC. The impact of proton pump inhibitor therapy on patients with liver disease. Aliment Pharmacol Ther. 2016;44:1213–1223.PubMedCrossRef

42.

Lewis DS, Lee TH, Konanur M et al. Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. J Vasc Interv Radiol. 2019;30:163–169.PubMedCrossRef

43.

Mahmud N, Serper M, Taddei TH, Kaplan DE. The association between proton pump inhibitor exposure and key liver-related outcomes in patients with cirrhosis: a Veterans Affairs cohort study. Gastroenterology. 2022.

44.

Dai R, Sag AA, Martin JG et al. Proton pump inhibitor use is associated with increased rates of post-TIPS hepatic encephalopathy: Replication in an independent patient cohort. Clin Imaging. 2021;77:187–192.PubMedCrossRef

45.

Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther. 2012;36:866–874.PubMedPubMedCentralCrossRef

46.

Tapper EB, Henderson JB, Parikh ND, Ioannou GN, Lok AS. Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis. Hepatol Commun. 2019;3:1510–1519.PubMedPubMedCentralCrossRef

47.

Dam G, Vilstrup H, Andersen PK, Bossen L, Watson H, Jepsen P. Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites. Liver Int. 2019;39:514–521.PubMedCrossRef

48.

Hu C, Anjur V, Saboo K et al. Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis. Am J Gastroenterol. 2021;116:336–346.PubMedCrossRef

49.

Bajaj JS, O’Leary JG, Reddy KR et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology. 2012;56:2328–2335.PubMedCrossRef

50.

De Franchis R, Bosch J, Garcia-Tsao G et al. Baveno VII–Renewing consensus in portal hypertension. Journal of hepatology. 2022;76:959–974.PubMedCrossRef

51.

Imhann F, Bonder MJ, Vila AV et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–748.PubMedCrossRef

52.

Jackson MA, Goodrich JK, Maxan M-E et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–756.PubMedCrossRef

53.

Freedberg DE, Toussaint NC, Chen SP, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149:883–885. e889.

54.

Brandl K, Schnabl B. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease? Expert review of gastroenterology & hepatology. 2015;9:1069–1076.CrossRef

55.

Chen P, Stärkel P, Turner JR, Ho SB, Schnabl B. Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology. 2015;61:883–894.PubMedCrossRef

56.

Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clinical Gastroenterology and Hepatology. 2013;11:483–490.PubMedCrossRef

57.

Garcia-Martinez I, Francés R, Zapater P et al. Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis. Journal of Gastroenterology and Hepatology. 2015;30:147–154.PubMedCrossRef

58.

Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clinical gastroenterology and hepatology. 2011;9:727–738.PubMedCrossRef

59.

Arroyo V, Angeli P, Moreau R et al. The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. Journal of hepatology. 2021;74:670–685.PubMedCrossRef

Titel: Proton Pump Inhibitors Increases Longitudinal Risk of Mortality, Decompensation, and Infection in Cirrhosis: A Meta-Analysis
verfasst von: Zhen Yu Wong
Jia Hong Koh
Mark Muthiah
Benjamin Koh
Elden Yen Hng Ong
Christen En Ya Ong
Kai Qi Ou
Wen Hui Lim
Darren Jun Hao Tan
Douglas Chee
Kewin Tien Ho Siah
Yujun Wong
Apichat Kaewdech
Karn Wijarnpreecha
Anand V. Kulkarni
Benjamin Nah
Daniel Q. Huang
Mazen Noureddin
Cheng Han Ng
Margaret Teng
Publikationsdatum: 15.11.2023
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 1/2024
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-023-08150-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Proton Pump Inhibitors Increases Longitudinal Risk of Mortality, Decompensation, and Infection in Cirrhosis: A Meta-Analysis